This international collaborative trial, sponsored by Roche pharmaceuticals, is the first gene therapy trial for a neurodegenerative disease of the central nervous system. If successful, the trial could have implications not just for Huntington’s disease but also genetically similar conditions such as the spinocerebellar ataxias.
Read more (Nuffield Department of Clinical Neuroscience website)